<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2023">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03080545</url>
  </required_header>
  <id_info>
    <org_study_id>PTC01</org_study_id>
    <nct_id>NCT03080545</nct_id>
  </id_info>
  <brief_title>Enstilar in Combination With Biologic Agents</brief_title>
  <official_title>An Open-Label, Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Biologic Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Psoriasis Treatment Center of Central New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Psoriasis Treatment Center of Central New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients receiving biologic therapy with 5% or less body surface area will receive Enstilar
      topical foam for 16 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A two-phase, single center, observational study of 25 subjects to assess 4 weeks of
      adjunctive therapy of Enstilar® QD followed by 12 weeks QD on two consecutive days a week to
      patients with ≤5% BSA who are receiving biologic therapy for at least 24 weeks
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2017</start_date>
  <completion_date type="Anticipated">November 15, 2017</completion_date>
  <primary_completion_date type="Anticipated">October 25, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physician global assessment multiplied by body surface area improvement after 16 weeks of Enstilar® adjunctive therapy</measure>
    <time_frame>16 weeks</time_frame>
    <description>pga x bsa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment</measure>
    <time_frame>16 weeks</time_frame>
    <description>PGA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Surface area</measure>
    <time_frame>16 weeks</time_frame>
    <description>BSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dermatology life quality index; TSQ-9 Treatment Satisfaction Questionnaire</measure>
    <time_frame>16 weeks</time_frame>
    <description>satisfaction determined by patient reported outcomes</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Open Label Enstilar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>open label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enstilar 0.005%-0.064% Topical Foam</intervention_name>
    <description>Topical foam</description>
    <arm_group_label>Open Label Enstilar</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female adults ≥ 18 years of age.

          2. Diagnosis of chronic plaque-type psoriasis.

          3. Able to give written informed consent prior to performance of any study related
             procedures.

          4. Treated with a biologic agent for a minimum of 24 weeks at baseline.

          5. Plaque-type psoriasis as defined at screening and baseline by BSA ≤ 5%.

          6. Females of childbearing potential (FCBP) must have a negative pregnancy test at
             Screening and Baseline. FCBP who engage in activity in which conception is possible
             must use one of the approved contraceptive options: hormonal contraception;
             intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female
             condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive
             sponge with spermicide.

          7. Subject must be in general good health (except for psoriasis) as judged by the
             Investigator, based on medical history, physical examination.

        Exclusion Criteria:

          1. &gt;5% Body Surface Area

          2. Any condition, which would place the subject at unacceptable risk if he/she were to
             participate in the study.

          3. Pregnant or breast feeding, or considering becoming pregnant during the study.

          4. Use of any investigational drug within 4 weeks prior to randomization, or within 5
             pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer).

          5. Use of oral systemic medications for the treatment of psoriasis within 4 weeks
             (includes, but not limited to, oral corticosteroids, methotrexate, acitretin,
             apremilast and cyclosporine).

          6. Patient used other topical therapies to treat within 2 weeks of the Baseline Visit
             (includes, but not limited to, topical corticosteroids, vitamin D analogs, or
             retinoids).

          7. Patient received UVB phototherapy within 2 weeks of Baseline.

          8. Patient received PUVA phototherapy within 4 weeks of Baseline.

          9. Patient has a known hypersensitivity to the excipients of Enstilar® as stated in the
             label.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jerry Bagel, MD</last_name>
    <phone>6094434500</phone>
    <email>dreamacres1@aol.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elise Nelson</last_name>
    <phone>6094434500</phone>
    <phone_ext>1402</phone_ext>
    <email>enelson@windsordermatology.com</email>
  </overall_contact_backup>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>March 2, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
